Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn, the Swiss Group focused on building quality cancer care, announces today that its recently launched Helsinn Integrative Care division is meeting the cancer community at booth 6033 at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, Chicago, Illinois.

A growing number of cancer patients seek supplements and herbs to address cancer or cancer therapies related issues without their oncologist's support and awareness, posing the problem of self-management in the delicate field of cancer care.

Helsinn Integrative Care aims to bridge the gap between patients' growing interest in self-management and better tolerance to the adverse effects of cancer and its treatments, and the lack of clinical evidence and oncologist support for the use of these products. Helsinn Integrative Care seeks to bring "qualified" products to market which support the areas of highest patient needs, but backed with solid evidence.

Helsinn Integrative Care has a portfolio of products including Gelclair®, Helsinn's oral gel to relieve the pain of oral mucositis. The company is investigating a range of products presently in development for the U.S. market, from XonRid, a topical gel for radiotherapy-induced dermatitis, to amIXea, a soluble mix including the nine essential amino acids for musculoskeletal support. Helsinn, as a trusted provider of cancer supportive care products, believes that it has an important role to play in signposting quality within this expanding new market.

The company's long-term vision is to offer options to people with cancer in all of their needs, not only with pharmaceutical products, but also through medical devices, supplements and medical foods. Historically, Helsinn has a leading position in cancer supportive care with market-leading cancer supportive care products such as Aloxi® (palonosetron), for chemotherapy-induced nausea and vomiting (CINV) and Akynzeo®, Helsinn's new oral fixed dose combination of a highly-selective NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist.

Helsinn Integrative Care looks forward to welcoming you at ASCO booth 6033 and to introducing you to its strategy and products.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI outperforms peers in medical oncology quiz, yet some mistakes could be harmful